Opaleye Management Inc. Theseus Pharmaceuticals, Inc. Transaction History

Opaleye Management Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$7.28 - $11.82 $796,432 - $1.29 Million	109,400 Added 22.41%	597,500 $5.57 Million
Q1 2023 May 12, 2023	SELL	$5.21 - $14.05 $244,349 - $658,945	-46,900 Reduced 8.77%	488,100 $4.33 Million
Q4 2022 Feb 10, 2023	BUY	$4.69 - $8.36 $1.47 Million - $2.63 Million	314,350 Added 142.47%	535,000 $2.66 Million
Q3 2022 Nov 14, 2022	BUY	$5.7 - $8.68 $1.07 Million - $1.63 Million	188,350 Added 583.13%	220,650 $1.28 Million
Q2 2022 Aug 15, 2022	BUY	$5.04 - $14.05 $162,792 - $453,815	32,300 New	32,300 $179,000

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.